Latest news with #osteoporosis
Yahoo
a day ago
- Health
- Yahoo
Weighted vests are 'great' for women in menopause. I put one to the test — and it's on sale on Amazon
After a recent bone density scan alarmed me, I started looking for ways to easily incorporate strength training into my daily walks and workouts. A while back, I had a bone density scan to assess how strong my bones were, and I was shocked by the results. The early menopause I had been put into as treatment for my breast cancer, as well as the medication I was taking to limit the estrogen supply in my body, had taken its toll on my already slight frame. My bones were weaker than they had ever been, putting me at an increased risk for fractures and osteoporosis. According to Dr. Allison Rhodes, a dual board-certified doctor in internal and obesity medicine, that's a common issue women face as they age. "During menopause, women experience a decline in estrogen, which is a hormone that is key to maintaining bone density," she says. "As women, we need to look for other ways to preserve our bone health." Quick shop: My doctor insisted I immediately increase my vitamin D dosage, incorporate more calcium-rich food into my diet, and add more weight training exercises to my workouts. But I also noticed more women walking in my neighbourhood with weighted vests — and wondered if they might help improve my bone strength. I ended up buying this bestselling ZELUS Weighted Vest and spoiler alert: I'm obsessed. Keep reading for my full review and see why experts recommend weight vests for aging women. The details The strength training vest is crafted with skin-friendly neoprene fabric and weighted with durable and evenly distributed iron sand. Looking to wear this during your walks around the neighbourhood? Then you'll appreciate the detachable front zipper pockets to safely store your cell phone and keys. There's also a rear elastic mesh pocket for additional on-the-go storage. The reflective stripes mean added security during your evening runs. The cushioned shoulder straps and non-chafing material make the vest an ideal accessory for even the longest workouts. The adjustable buckle straps allow for a more custom fit, and the vest itself is available in various weights from 6 lbs to 30 lbs. What I like about it I'm all about easy ways to make my workouts count more: I wore this vest daily while walking on the highest incline on the treadmill at a very brisk pace — and according to my watch, burned more calories than when I wasn't wearing it. I stood taller on the treadmill, was able to go at a faster clip, and overall just felt stronger. I'm not a super big person (I weigh 115 lbs and am about 5'5") and went with the 6 lb size, but just having this weighted vest on my shoulders made me feel more grounded, which meant I could work out for longer. You can wear it anywhere: I also wore it while I was cleaning the house, doing laundry and working at my computer — and noticed I sat up taller and kept my muscles more engaged. Your abs will thank you for it: It even helped with my ab workouts. I wore it while holding my two-minute front and side planks, and I felt more of a burn in my belly. Great for anyone who has had a double mastectomy: As a breast cancer survivor who had a double mastectomy, I am very cautious of anything resting on that sensitive chest area. The vest fell perfectly on my body. It didn't feel heavy or uncomfortable, and I often forgot I even had it on. The buckle in the front can be easily adjusted, and for my size, the 6 lbs of weight offered just the right amount of resistance. Room for improvement I wasn't thrilled with how it smelled: OK, functionally, this vest was amazing — but it smelled awful when it came out of the package — to the point that the chemical scent distracted me from my workouts the first few times I wore it. Even now, after wearing it regularly for the past two months, the smell still lingers. I guess you could rub it with a dryer sheet or some other deodorizer, but I don't think you should be required to do that to improve the scent. It's not a deal breaker, but it's something to be mindful of, especially if you're sensitive to smells. What other shoppers are saying ⭐️4.2/5 stars 💬 8,500+ reviews 🏅"Easily adds intensity to a simple walk." Reviewers are "impressed" with the vest, with one saying that it "really helps you burn" extra calories in a "shorter amount of time." $37 $47 at Amazon "Obsessed with this vest!" adds another shopper, who loves that the vest doesn't "flop" around when running. Another person said the "comfortable" vest is "great for muscles and bones" and loves wearing it daily while cooking and doing housework. They say it also "makes [their] posture better." This vest is a total "game changer" said one customer, stating the impact of the vest was even "greater" than they expected. "Don't sleep on" getting a weighted vest, they advised. However, if you have a large chest, this may not be for you. One shoppers cautioned it's best for "flat chested" users and, like me, said it "definitely smelled like plastic" after they opened the package. Are weighted vests good for you? Do weighted vests work? Experts weigh in Tara De Leon, a personal trainer and menopause coach, says that "weighted vests are particularly great for women in menopause because they improve bone density, enhance muscular strength, support joint health, improve balance, decreases fall risk and improve posture." $37 $47 at Amazon She adds they do that "all without the excessive strain that high impact exercise can cause," and says she likes them more than ankle or wrist weights, which "can throw off your gait." Rhodes also says she recommends the vest for women in menopause — as well as peri- and post-menopausal people, because "adding a weighted vest can not only turn a simple walk into a workout, but one that counts as resistance training." Why is this important? According to Rhodes, both men and women can start to experience muscle loss as early as in their late 30s and 40s (yikes!). In order to prevent injury and illness, "...maintaining muscle mass and strength is critical for both men and women to ensure optimal mobility and balance as we age," she says. But that said, experts do say there are a few key things to keep in mind before you buy a weighted vest to ensure you won't injure yourself. "Weighted vests should fit snugly and evenly distribute weight to limit risk of injury," Rhodes cautions. She says the weight of the vest should be dependent on your current body weight, and recommends starting with a vest that's 5-10 per cent your weight. For example, if you weigh 200 lbs., a good starting point would be a 10-lb. vest. It's also a good idea to start slowly when working a weighted vest into your routine. Michael Betts, a personal trainer with more than 30 years of experience, recommends "add[ing] weighted vest training gradually into an existing exercise routine that includes strength training and balance work." Is there anyone who should avoid weighted vests? Dr. Chris Mohr, a fitness and nutrition advisor at BarBend, advises that "people with existing joint issues should be cautious, as excessive weight can increase strain, particularly on the knees and lower back." All the experts agree that if you have osteoporosis, arthritis or other health conditions, you should consult your doctor before trying out a weighted vest. Should you buy it? For me, working out while wearing a weighted vest has become my new normal. I love the way it makes me feel, the endurance it gives me, and the added boost to my metabolism it provides. It's super comfortable, and the offensive odour it had when I first got it has almost worn off. Mind you, I have no plans to go up in weight, and for my smaller frame, the 6 lb vest is the perfect fit. I'm inclined to agree with one reviewer and call the ZELUS weighted vest a "game changer." While experts agree that it can make a major impact to your workout, they do caution that if you have existing health issues, you should consult your doctor before adding one to your routine. Meet the experts Allison Rhodes, MD, dual board-certified in internal medicine and obesity medicine, The Ohio State University Wexner Medical Center Tara De Leon, NSCA Personal Trainer of the Year and menopause coach Michael Betts, personal trainer and director at TRAINFITNESS Chris Mohr, PHD, RD, Fitness and Nutrition Advisor at BarBend
Yahoo
4 days ago
- Health
- Yahoo
'I'm an unpaid carer for my mum in Greenwich - it's like grieving your own life'
Seven years ago Denise Wilkins was a successful accountant who was regularly travelling across Europe for her work. Her career achievements were remarkable considering she had been simultaneously caring for her mum, Maureen Shields, since the age of 14 when she started to lose her sight. But in 2018 everything changed. Maureen woke up one morning and couldn't move. She'd developed osteoporosis, a condition which weakens bones and makes them more susceptible to fractures. Maureen had spinal fractures that prevented her movement and caused her excruciating pain. Denise was forced to give up the career she'd worked so hard to build to look after Maureen full-time. Denise, now 54, said: 'It's almost like grieving the loss of your own life. You're grieving because of the loss of what's happened to somebody else, and seeing somebody in constant pain is hard. "It's also just incredibly mentally and emotionally wearing having to not only deal with your own life's disappointments and problems, but also the emotions that they're going through.' Denise lives with her 89-year-old mum in a flat in Vanbrugh Hill, Greenwich and has said the experience has had a profound impact on her mental health and wellbeing, to the point that she's been prescribed antidepressants to cope. Never in doubt was it that she would be there for her mum, but the lack of support from the government for unpaid carers like her has led to burnout and a feeling of being abandoned. 'There's a lack of support, a lack of understanding, and a lack of recognition,' Denise said. 'I just don't think people really understand just how all time consuming it is, and to be honest, it is very emotionally draining.' After the osteoporosis diagnosis the family moved from Loughton in Essex – their home for over 20 years – to Greenwich in order to be closer to King's College Hospital and because they couldn't adapt their Essex home to Maureen's needs. Maureen had a series of operations which stabilised her condition, but it left her with virtually no mobility. Denise has looked after her mum on a near daily basis since then as she can't afford to get paid carers in to help. She praised the work the NHS did in treating Maureen, but was critical of the provision for care that is provided afterwards. She said: 'There is just this assumption that the family's going to step in. There is nothing wrong with that, but then you realise there is very little support out there to recognise what you've lost in your life. It was life-changing for her, but it was also life-changing for me.' Denise felt that since she started looking after her mother in 2018, she has massively missed out on living her own life. She said: 'I mean not just financially, career-wise, socially, but all hobbies and interests have been completely put on hold. Even things like your own fitness levels and personal relationships. 'You feel like it's not just the person who needs to be cared for whose life has changed. It's almost like you've got an illness too.' Denise said she even has trouble attending to her own medical needs due to the lack of available appointments. If she's not able to find someone to look after her mum at the time when a GP appointment is offered, she can't attend it. Denise said she has been on antidepressants for the past six years, something she directly attributed to the stress of being a full-time carer. She is often told by people to take a break, but that is something that is incredibly difficult for her because she would need to find someone Maureen is comfortable with, who is able to look after her and she is able to afford. Her own retirement is in doubt Since becoming a carer, Denise hasn't been able to pay into her pension. For work, she has been able to pick up some zero-hour flexible contracts for minimum wage. 'While you're going through this journey you talk to other people and you find that it's common across the board,' she said. 'You start to realise that if people weren't stepping in and doing what they were doing, the whole adult social care system would just collapse.' Denise was critical of the government's stance on adult social care. She said: 'I can remember for at least the last 10 years that it's going to be reviewed. There's been loads of these reports, and you just feel like saying to people, 'Come on, we need to address this'. 'We need to, not just as individuals but as a society, look at how we're going to handle this.' When asked what changes she would like to see the government make to adult social care and the role of carers, Denise said: 'I think they could really do a lot more in terms of allowing carers to have time off, especially with work. 'You're allowed to take two or three days' unpaid leave, but that's nothing. It doesn't even begin to cover the number of hospital appointments that you'll need to attend.' She also hoped that a system could be brought in that would allow for carers to be registered and recognised. 'It would allow us to be able to go to employers and people and say, 'I am a registered carer'.' Denise also wanted the government to recognise that often carers are skilled workers who could be put to use helping society if there was more of a push to get them to work from home. 'There's a whole skill base out there of people like me who have got the qualifications and have got the work experience,' she said. 'I think that's another frustrating thing. They go off and supposedly do these reviews, but they never ever seem to talk to us. We're not just sitting here complaining. We actually feel that we've got things we could suggest.' Protest outside Parliament In an attempt to drive the issue of carers into the public eye and onto the government agenda, Denise took part in a protest on Tuesday (July 22) outside Parliament. As she can't get away from her caring duties, Denise wasn't there in person. Her story, alongside those of several other unpaid carers, will be broadcast on LED screens outside government buildings in an attempt to get politicians to listen. The protest, which was set up by Uncommon Creative Studio and is backed by charity Carers Trust, has been launched in conjunction with a petition which calls on the government to give all unpaid carers the legal right to a break. Kirsty McHugh, CEO of Carers Trust, said: 'It's incredibly disappointing that the UK Government still hasn't given unpaid carers a right to respite. For decades, successive governments have depended on unpaid carers to provide social care on the cheap, which has delayed the need to come up with long-term funding and support. 'Whilst the government is focused on strengthening employment rights, it seems to have forgotten unpaid carers – who can't take a break at all.'
BBC News
12-07-2025
- Health
- BBC News
Essex teen who cannot eat or drink wants to make the most of life
A teenager who has never been able to eat or drink due to a rare condition said she was determined to make the most of life, despite her health from Stanford-le-Hope in Essex, had her bowel removed as a child and is fed via a tube to a major artery near her 14-year-old was also recently diagnosed with osteoporosis, a condition that weakens bones, and now uses a wheelchair."I just try and have a positive attitude," she said. "Sometimes it gets me down when I'm in pain, but most of the time I try not to let it bother me." Isla's condition is so rare that it does not have a name. She has infusions into her bloodstream for 18 hours a teenager also has issues with her immune system, liver and kidneys and has contracted sepsis several was attending high school until last year when she got sepsis and has not yet been able to return. "It hasn't been easy. I was doing so well at school, but the sepsis was a major setback, and I haven't been well enough to go back," she said. Isla loves going to music concerts and is looking forward to learning to drive when she turns 16.A recent Tate McRae concert was one of the best nights of her life, she said, even though she ended up crying herself to sleep with back also managed to go on a cruise with her family this year, after a battle to get insurance, but was in excruciating pain with her back throughout it. Her mother, Ashlee, gave up her job as a support worker for adults with learning difficulties when Isla was a baby, so she could care for friend recently created a GoFundMe page, which has seen donations of more than £3,000 towards a specialist wheelchair, instead of her current basic NHS said she was "so grateful" and "overwhelmed" by the said: "I would love Isla to get a bespoke wheelchair, which could mean she can just feel like a normal teenage girl for a bit and give her some independence."Isla doesn't realise how amazing she is. She is exceptionally brave and resilient."I look at her and I just beam with pride. I don't know how someone can go through so much and be so caring and kind and happy." Follow Essex news on BBC Sounds, Facebook, Instagram and X.
Yahoo
08-07-2025
- Health
- Yahoo
Celltrion USA announces U.S. launch of denosumab biosimilars, STOBOCLO® and OSENVELT® (denosumab-bmwo)
STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) are approved by FDA for all indications of PROLIA® (denosumab) and XGEVA® (denosumab) respectively[1],[2] STOBOCLO and OSENVELT, among the first wave of biosimilars referencing PROLIA and XGEVA respectively, are commercially available in the U.S. Celltrion further expands its portfolio, delivering cost-effective and high-quality biologic medicines to wider range of patients in the U.S. JERSEY CITY, N.J., July 7, 2025 /PRNewswire/ -- Celltrion USA today announced that STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo), biosimilars referencing PROLIA® (denosumab) and XGEVA® (denosumab) respectively, are commercially available in the United States. STOBOCLO is available in 60 mg/mL injection and is approved to treat postmenopausal women with osteoporosis at high risk for fracture, to increase bone mass in men with osteoporosis at high risk for fracture, to treat glucocorticoid-induced osteoporosis in men and women at high risk for fracture, to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer, and to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer.[1] OSENVELT is available in 120 mg/1.7 mL (70 mg/mL) injection and is indicated to prevent skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors, to treat adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity, and to treat hypercalcemia of malignancy refractory to bisphosphonate therapy.[2] "We are pleased to have achieved a global settlement with Amgen regarding our denosumab biosimilars," said Thomas Nusbickel, Chief Commercial Officer at Celltrion USA. "We are proud to introduce our denosumab biosimilars to the U.S. market, offering patients and healthcare professionals a valuable alternative treatment option. Building on our strong heritage in biosimilars, Celltrion remains committed to being a trusted partner for both patients and physicians, while contributing to the overall sustainability of healthcare systems." STOBOCLO and OSENVELT are supported by Celltrion's comprehensive patient support programs designed to help empower patients to navigate their treatment journeys. Celltrion offers a suite of resources, including the Celltrion CONNECT® Patient Support Program and the Celltrion CARES™ Co-pay Assistance Program. Patients who are uninsured may be able to receive STOBOCLO and OSENVELT at no cost. Visit and to learn more. Celltrion's biosimilars portfolio covers the areas of immunology, oncology, gastroenterology, allergy, and endocrinology. About STOBOCLO® (denosumab-bmwo) STOBOCLO® (denosumab-bmwo) is a receptor activator of NF-κb ligand (RANKL) inhibitor referencing PROLIA® (denosumab). STOBOCLO 60 mg/mL injection is approved by the FDA based on comprehensive data and clinical evidence confirming the therapeutic equivalence to PROLIA. In the U.S., STOBOCLO is approved to treat postmenopausal women with osteoporosis at high risk for fracture, to increase bone mass in men with osteoporosis at high risk for fracture, to treat glucocorticoid-induced osteoporosis in men and women at high risk for fracture, to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer, and to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. INDICATIONS STOBOCLO® (denosumab-bmwo) is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture to increase bone mass in men with osteoporosis at high risk for fracture or in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer of glucocorticoid-induced osteoporosis in men and women at high risk for fracture to increase bone mass in women at high risk for fracture receiving an adjuvant aromatase inhibitor therapy for breast cancer IMPORTANT SAFETY INFORMATION WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE Patients with advanced chronic kidney disease, including those on dialysis, face a higher risk of severe hypocalcemia after denosumab administration, with reported cases leading to hospitalization, life-threatening events, and fatalities. The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increases the risk of hypocalcemia in these patients Before starting STOBOCLO® (denosumab-bmwo) in advanced chronic kidney disease patients, assess for CKD-MBD. Treatment should be supervised by a healthcare provider experienced in diagnosing and managing CKD-MBD. STOBOCLO is contraindicated in hypocalcemia, pregnant women, and in patients with known hypersensitivity to denosumab. Severe Hypocalcemia: Ensure adequate calcium and vitamin D; monitor for severe hypocalcemia. Drug Products with Same Active Ingredient: Do not use with other denosumab products. Hypersensitivity: If an anaphylactic or other clinically significant allergic reaction occurs, initiate appropriate therapy and discontinue further use of STOBOCLO. Osteonecrosis of the Jaw (ONJ): ONJ can occur in patients on STOBOCLO. Conduct oral exams before treatment; maintain oral hygiene; consider discontinuation of STOBOCLO if ONJ develops. Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Monitor for thigh, hip, or groin pain; evaluate for fractures. Interruption of STOBOCLO therapy should be considered, pending a benefit-risk assessment, on an individual basis. Multiple Vertebral Fractures (MVF) Following Discontinuation of Treatment: Increased risk post-discontinuation of denosumab; transition to alternative therapy if discontinuing STOBOCLO. Serious Infections: Higher risk in denosumab users; assess benefit-risk profile, especially in immunocompromised patients. Assess the benefit-risk profile before starting STOBOCLO and reconsider its use if serious infections develop. Dermatologic Adverse Reactions: Consider discontinuing STOBOCLO if severe dermatitis, eczema, or rashes occur. Musculoskeletal Pain: Consider discontinuation of STOBOCLO if severe pain develops. Bone Turnover Suppression: In clinical trials in women with postmenopausal osteoporosis, denosumab significantly suppressed bone remodelling; patients should be monitored for these outcomes. Hypercalcemia in Pediatrics Patients with Osteogenesis Imperfecta: Not for pediatric use; hypercalcemia reported in patients osteogenesis imperfecta treated with denosumab products. Most common Adverse Reactions: In (>5%) of patients with: Postmenopausal osteoporosis were back pain, pain in extremity, hypercholesterolemia, musculoskeletal pain, and cystitis. Pancreatitis has been reported in clinical trials. Male osteoporosis were back pain, arthralgia, and nasopharyngitis. Glucocorticoid-induced osteoporosis (> 3%) were back pain, hypertension, bronchitis, and headache. Bone loss due to hormone ablation for cancer (≥ 10%) were arthralgia and back pain. Pain in extremity and musculoskeletal pain have also been reported in clinical trials. For more information, see Full Prescribing Information. About OSENVELT® (denosumab-bmwo) OSENVELT® (denosumab-bmwo) is a receptor activator of NF-κb ligand (RANKL) inhibitor referencing XGEVA® (denosumab). OSENVELT 120 mg/1.7 mL (70 mg/mL) injection is approved by the FDA based on a robust clinical trial and comprehensive data confirming the therapeutic equivalence to XGEVA. In the U.S., OSENVELT is indicated to prevent skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors, to treat adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity, and to treat hypercalcemia of malignancy refractory to bisphosphonate therapy. INDICATION OSENVELT® (denosumab-bmwo) is indicated for: Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity. Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy. IMPORTANT SAFETY INFORMATION Contraindications: Patients with hypocalcemia or with known clinically significant hypersensitivity to denosumab products. Drug Products with Same Active Ingredient. Patients receiving OSENVELT should not receive other denosumab products concomitantly. Hypersensitivity. If an anaphylactic or other clinically significant allergic reaction occurs, initiate appropriate therapy and discontinue further use of OSENVELT. Hypocalcemia. Severe hypocalcemia can occur, and fatal cases have been reported. Monitor calcium levels and calcium and vitamin D intake. Osteonecrosis of the Jaw (ONJ): ONJ can occur in patients on OSENVELT. Conduct oral exams and appropriate preventive dentistry before and during treatment; maintain oral hygiene and avoid invasive dental procedures; consider discontinuation of OSENVELT if ONJ develops. Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Monitor for thigh, hip, or groin pain; evaluate for fractures. Interruption of OSENVELT therapy should be considered, pending a benefit-risk assessment, on an individual basis. Hypercalcemia Following Treatment Discontinuation in Patients with Giant Cell Tumor of Bone and in Patients with Growing Skeletons. Clinically significant hypercalcemia, potentially requiring hospitalization, can occur within a year after stopping denosumab in patients with giant cell tumor of bone or growing skeletons; monitor serum calcium and manage calcium and vitamin D needs post-discontinuation. Multiple Vertebral Fractures (MVF) Following Treatment Discontinuation. Increased risk post-discontinuation of denosumab; evaluate for risk for vertebral fractures after discontinuing OSENVELT. Embryo-Fetal Toxicity. Denosumab may cause fetal harm; verify pregnancy status before starting OSENVELT and advise effective contraception during treatment and for 5 months after the last dose. Most common Adverse Reactions: Bone Metastasis from Solid Tumors (≥ 25%) were fatigue/asthenia, hypophosphatemia, and nausea. In patients (≥ 10%) with: Multiple Myeloma were diarrhea, nausea, anemia, back pain, thrombocytopenia, peripheral edema, hypocalcemia, upper respiratory tract infection, rash, and headache; Giant Cell Tumor of Bone were arthralgia, headache, nausea, back pain, fatigue, and pain in extremity. Hypercalcemia of Malignancy (> 20%) were nausea, dyspnea, decreased appetite, headache, peripheral edema, vomiting, anemia, constipation, and diarrhea. For more information, see Full Prescribing Information. About Celltrion, Inc. Celltrion is a leading biopharmaceutical company that specializes in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people's lives worldwide. Celltrion is a pioneer in the biosimilar space, having launched the world's first monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, hematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific innovation and deliver quality medicines. For more information, please visit our website and stay updated with our latest news and events on our social media - LinkedIn, Instagram, X, and Facebook. About Celltrion USA Celltrion USA is Celltrion's U.S. subsidiary established in 2018. Headquartered in New Jersey, Celltrion USA is committed to expanding access to innovative biologics to improve care for U.S. patients. Celltrion's FDA-approved biosimilar products in immunology, oncology, hematology, and endocrinology include: INFLECTRA® (infliximab-dyyb), TRUXIMA® (rituximab-abbs), HERZUMA® (trastuzumab-pkrb), VEGZELMA® (bevacizumab-adcd), YUFLYMA®(adalimumab-aaty), AVTOZMA® (tocilizumab-anho), STEQEYMA® (Ustekinumab-stba) STOBOCLO® (denosumab-bmwo), OSENVELT® (denosumab-bmwo), and OMLYCLO® (omalizumab-igec), as well as the novel biologic ZYMFENTRA® (infliximab-dyyb). Celltrion USA will continue to leverage Celltrion's unique heritage in biotechnology, supply chain excellence and best-in-class sales capabilities to improve access to high-quality biopharmaceuticals for U.S. patients. For more information, please visit and stay updated with our latest news and events on our social media - LinkedIn. FORWARD-LOOKING STATEMENT Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion, Inc. and its subsidiaries that may constitute forward-looking statements, under pertinent securities laws. These statements may be also identified by words such as "prepares", "hopes to", "upcoming", "plans to", "aims to", "to be launched", "is preparing", "once gained", "could", "with the aim of", "may", "once identified", "will", "working towards", "is due", "become available", "has potential to", the negative of these words or such other variations thereon or comparable terminology. In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion, Inc. and its subsidiaries' management, of which many are beyond its control. Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect to the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties associated with the company's business, including the risk factors disclosed in its Annual Report and/or Quarterly Reports, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such statements. Celltrion, Inc. and its subsidiaries undertake no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. Trademarks STOBOCLO® and OSENVELT® are registered trademarks of Celltrion, and XGEVA® are registered trademarks of Amgen Inc. References [1] STOBOCLO U.S. prescribing information (2025) [2] OSENVELT U.S. prescribing information (2025) US-CT-P41-25-00006 For further information please contact:Andria Arenaaarena@ 516-578-0057 View original content to download multimedia: SOURCE Celltrion Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
07-07-2025
- Health
- Medscape
Exercise Adherence Support Boosts Vertebral Fracture Rehab
TOPLINE: A tailored exercise adherence intervention integrated into physiotherapy rehabilitation enhanced mobility outcomes in people with vertebral fragility fractures. At 12 months, participants who received adherence support demonstrated better functional mobility and exercise capacity than those who received standard rehabilitation. METHODOLOGY: Researchers conducted a randomised controlled trial to evaluate whether adding a tailored, theory-driven adherence support intervention to a standard physiotherapy exercise programme improves outcomes in people with osteoporotic vertebral fragility fractures. They enrolled 126 participants (mean age, 72.7 years; 83% women) from eight hospitals in England and Wales, all of whom had at least one vertebral fragility fracture confirmed using radiography, X-ray, MRI, or DEXA; had experienced back pain in the past 12 months; and were able to walk 10 m independently. Participants were randomly assigned to either the control group or the intervention group (n = 63 each), where both received progressive exercise rehabilitation including musculoskeletal assessments, treatment sessions, and a home exercise plan comprising strength, posture, and balance exercises over 4 months. The intervention group also received an integrated exercise adherence intervention that used a motivational interviewing approach with goal setting and three or more behaviour change techniques. The primary outcome was the Timed-Up and Go test at 12 months that assessed balance, lower limb function, functional mobility, and fall risk, whereas secondary outcomes included measures of physical functions and self-reported outcomes. TAKEAWAY: At the 12-month follow-up, the intervention group demonstrated a faster performance in the Timed-Up and Go test than the control group by 2.1 seconds (P < .01), which was clinically significant. In the 6-minute walk test that determines functional exercise capacity, the intervention group covered a significantly greater walking distance than the control group (mean difference, 24.5 m; P < .01). No significant differences were observed between groups in other outcome measures of physical functions including thoracic kyphosis, test of dynamic standing balance, and test of shoulder and back muscle endurance. No intervention-related serious adverse events or adverse events were reported in either group. IN PRACTICE: "The results of this study provide evidence that integrating tailored support for exercise behaviour throughout physiotherapy exercise rehabilitation for people with VFF [vertebral fragility fractures] can help to sustain effects and improve longer-term functional mobility outcomes," the authors wrote. SOURCE: This study was led by Karen L. Barker, Oxford University Hospitals NHS Foundation, Oxford, England. It was published online on June 30, 2025, in Osteoporosis International. LIMITATIONS: Physiotherapists and participants were necessarily aware of their allocated group. Physiotherapists had differing levels of knowledge and experience of using the motivational interviewing approach. DISCLOSURES: This study received support from the Chartered Society of Physiotherapy Charitable Trust. The authors reported no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
